Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $19.5 million.

  • Revolution Medicines' Change in Account Payables rose 80104.02% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 52869.91%. This contributed to the annual value of -$6.5 million for FY2024, which is 11991.13% down from last year.
  • Revolution Medicines' Change in Account Payables amounted to $19.5 million in Q3 2025, which was up 80104.02% from $8.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Change in Account Payables registered a high of $29.4 million during Q4 2024, and its lowest value of -$29.0 million during Q1 2024.
  • In the last 5 years, Revolution Medicines' Change in Account Payables had a median value of $189000.0 in 2021 and averaged $2.9 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 531746.03% in 2022, then plummeted by 265809.52% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Change in Account Payables stood at $2.6 million in 2021, then plummeted by 158.57% to -$1.5 million in 2022, then skyrocketed by 1712.81% to $24.3 million in 2023, then rose by 20.81% to $29.4 million in 2024, then tumbled by 33.44% to $19.5 million in 2025.
  • Its Change in Account Payables stands at $19.5 million for Q3 2025, versus $8.8 million for Q2 2025 and -$8.3 million for Q1 2025.